Pharsight

Abbvie Endocrine Inc patents expiration

1. Lupron Depot patents expiration

LUPRON DEPOT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815801 ABBVIE ENDOCRINE INC Controlled release composition and method of producing the same
Jun, 2022

(1 year, 2 months ago)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(7 years from now)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 22 December, 1995

Treatment: Palliative treatment of prostate cancer

Dosage: INJECTABLE;INJECTION

More Information on Dosage

LUPRON DEPOT family patents

Family Patents

2. Lupron Depot-ped Kit patents expiration

LUPRON DEPOT-PED KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9617303 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Mar, 2028

(4 years from now)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength (NS) Apr 14, 2026

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 16 April, 1993

Treatment: Treatment of pediatric patients with central precocious puberty

Dosage: POWDER;INTRAMUSCULAR

More Information on Dosage

LUPRON DEPOT-PED KIT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic